NetScientific: refinanced and focused on enhancing value

0
12
  • NetScientific to raise funds to accelerate its renaissance
NetScientific PLC -

Quick facts: NetScientific PLC

Follow

View company profile

NetScientific PLC is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally.

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities.

10 Jun 2021

NetsScientific PLC (LON:NSCI) received a strong response to its share placing, raising GBP7.7mln, which was around 10% more than originally anticipated.

A total of 5.96mln shares were placed with new and existing investors at 130p a spell.

Speaking to Proactive, chief executive officer Dr Ilian Iliev said he was delighted with the response, saying it was a strong validation of the company’s model.

Iliev felt the enthusiastic response reflected what NetScientific’s management team sees as the gap between the company’s market capitalisation and the fair value of the business.

Read more

08 Jun 2021

() portfolio company, PDS Biotechnology () said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression.

Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS’s candidate PDS0101 in combination with two immune-modulating agents on 25 patients.

Read more

07 Jun 2021

‘s () ProAxsis subsidiary has struck a licensing deal with PLC () over the validation and global commercialisation of an assay associated with Coronavirus vaccines.

The subsidiary of the AIM-listed company will take responsibility for completing the validation and global commercialisation of an enzyme-linked immunosorbent assay (ELISA) developed by an internal research team at for vaccines associated with SARS-CoV-2, which is the virus associated with COVID-19.

Read more

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma (LON:DEST) presenting at the Cenkos Growth & Innovation Forum…

Destiny Pharma (LON:DEST) presenting at the Cenkos Growth & Innovation Forum – Tuesday 8th June 2021

Cenkos Growth & Innovation Forum – Tuesday 8th June 2021

Join Cenkos and Proactive at the Growth & Innovation Forum on Tuesday the 8th June 2021 from 9am onwards. Meet…

3 hours, 9 minutes ago

5 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here